The US FDA has approved Mesoblast's Ryoncil (remestemcel-L-rknd) for treating steroid-refractory acute graft-versus-host disease (SR-aGVHD) in pediatric patients 2 months and older. …
FDA approves Mesoblast's cell therapy to treat steroid-refractory acute graft-versus-host disease
December 19, 2024 Australian Biotech
Latest Video
New Stories
-
'Found irregularities and anomalies in the instruments of delegation from the minister'
December 20, 2024 - - Latest News -
FDA approves Mesoblast's cell therapy to treat steroid-refractory acute graft-versus-host disease
December 19, 2024 - - Australian Biotech -
Wholesalers secure five-year agreement with the Government
December 19, 2024 - - Latest News -
When the Government funds a health technology, the community makes certain assumptions
December 19, 2024 - - Latest News -
If this decision to undermine the TGA reflects a policy decision, be transparent about it
December 18, 2024 - - Latest News -
Race Oncology appoints Opthea founder to its board
December 18, 2024 - - Australian Biotech -
New listings and higher prescription volumes driving PBS spend
December 18, 2024 - - Latest News